Pages that link to "Q28473419"
Jump to navigation
Jump to search
The following pages link to Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth (Q28473419):
Displaying 50 items.
- Targeting TGF-β signaling in cancer (Q27012443) (← links)
- Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy (Q27021750) (← links)
- Complexities of TGF-β targeted cancer therapy (Q27693607) (← links)
- Treatment of multiple myeloma bone disease: experimental and clinical data. (Q30868833) (← links)
- Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics (Q34038854) (← links)
- Bone disease in multiple myeloma: pathophysiology and management. (Q34045789) (← links)
- Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. (Q34551206) (← links)
- Bone Anabolic Agents for the Treatment of Multiple Myeloma (Q35603116) (← links)
- Thrombospondin-1 inhibits osteogenic differentiation of human mesenchymal stem cells through latent TGF-β activation (Q36024744) (← links)
- Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast (Q36086488) (← links)
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma (Q36206430) (← links)
- Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities (Q36447553) (← links)
- Targeting the TGFβ signalling pathway in disease (Q36462348) (← links)
- Novel Bruton's tyrosine kinase inhibitors currently in development (Q36673755) (← links)
- Small Molecule Inhibition of Transforming Growth Factor Beta Signaling Enables the Endogenous Regenerative Potential of the Mammalian Calvarium. (Q36925808) (← links)
- Mechanisms of multiple myeloma bone disease (Q37056408) (← links)
- Kinase inhibitors as potential agents in the treatment of multiple myeloma (Q37697253) (← links)
- Tumor-host cell interactions in the bone disease of myeloma (Q37771082) (← links)
- Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma (Q37946702) (← links)
- Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. (Q38736038) (← links)
- Molecular mechanisms, current management and next generation therapy in myeloma bone disease. (Q38749233) (← links)
- Adipose, Bone, and Myeloma: Contributions from the Microenvironment. (Q38876521) (← links)
- Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. (Q38999733) (← links)
- Targeting TGF-β Signaling for Therapeutic Gain (Q39155151) (← links)
- Transforming growth factor-β: A therapeutic target for cancer (Q39346505) (← links)
- Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate (Q39402922) (← links)
- KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts (Q39477279) (← links)
- Co-culture of human bone marrow stromal cells with endothelial cells alters gene expression profiles (Q39641026) (← links)
- Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma (Q39758292) (← links)
- The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). (Q41689098) (← links)
- Differential Signalling Through ALK-1 and ALK-5 Regulates Leptin Expression in Mesenchymal Stem Cells (Q42235819) (← links)
- A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration (Q42317482) (← links)
- Bone-Conditioned Medium Inhibits Osteogenic and Adipogenic Differentiation of Mesenchymal Cells In Vitro (Q42807602) (← links)
- Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib (Q42818861) (← links)
- Upregulation of long non-coding RNA HIF 1α-anti-sense 1 induced by transforming growth factor-β-mediated targeting of sirtuin 1 promotes osteoblastic differentiation of human bone marrow stromal cells (Q43196446) (← links)
- Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. (Q45756098) (← links)
- Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease (Q47243282) (← links)
- Pathogenesis of bone disease in multiple myeloma: from bench to bedside (Q47734632) (← links)
- Mechanisms of bone destruction in multiple myeloma (Q47756922) (← links)
- Direct phenotypic conversion of human fibroblasts into functional osteoblasts triggered by a blockade of the transforming growth factor-β signal. (Q54977433) (← links)
- Myeloma bone disease: Pathophysiology and management. (Q55209965) (← links)
- Bone-targeted agents in multiple myeloma. (Q55395268) (← links)
- Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target? (Q55471455) (← links)
- Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models (Q57463395) (← links)
- Osteosarcoma cells promote the production of pro-tumor cytokines in mesenchymal stem cells by inhibiting their osteogenic differentiation through the TGF-β/Smad2/3 pathway (Q60248825) (← links)
- In vitro cell response on CP-Ti surfaces functionalized with TGF-β1 inhibitory peptides (Q61736748) (← links)
- Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma (Q64067106) (← links)
- Multiple Myeloma and Fatty Acid Metabolism (Q64266770) (← links)
- Small molecule inhibitor of TGF-β signaling enables robust osteogenesis of autologous GMSCs to successfully repair minipig severe maxillofacial bone defects. (Q64898955) (← links)
- TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects (Q89777495) (← links)